Bihoreau; Nicolas

Patent Applications and Registrations

Patent applications and USPTO patent grants for Bihoreau; Nicolas.The latest application filed is for "monoclonal antibodies with enhanced adcc function".

Company Profile

0.31.29

Bihoreau; Nicolas - Orsay FR

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Recombinant or transgenic factor VII composition, each factor VII molecule having two N-glycosylation sites with defined glycan units Grant 10,364,425 - Chtourou , et al.	2019-07-30
Recombinant or transgenic factor VII composition, each factor VII molecule having two N-glycosylation sites with defined glycan units Grant 10,344,272 - Chtourou , et al. July 9, 2	2019-07-09
Monoclonal antibodies with enhanced ADCC function Grant 10,081,683 - Beliard , et al. September 25, 2	2018-09-25
Use of ADCC-optimized antibodies for treating low-responder patients Grant 9,879,089 - Bourel , et al. January 30, 2	2018-01-30
Monoclonal Antibodies With Enhanced Adcc Function App 20180002442 - BELIARD; ROLAND ; et al.	2018-01-04
Method for purifying active GLA-domain coagulation proteins Grant 9,850,477 - Perret , et al. December 26, 2	2017-12-26
Monoclonal antibodies with enhanced ADCC function Grant 9,718,889 - Beliard , et al. August 1, 2	2017-08-01
Monoclonal antibodies with enhanced ADCC function Grant 9,718,890 - Beliard , et al. August 1, 2	2017-08-01
Monoclonal antibodies with enhanced ADCC function Grant 9,708,409 - Beliard , et al. July 18, 2	2017-07-18
Method for purifying GLA-domain coagulation proteins Grant 9,359,610 - Perret , et al. June 7, 2	2016-06-07
Method For Purifying Active Gla-domain Coagulation Proteins App 20160138001 - Perret; Gerard ; et al.	2016-05-19
Novel Medicaments Comprising An Antibody Composition Enriched With Predominant Charge Isoform App 20160046722 - Chevreux; Guillaume ; et al.	2016-02-18
Method for purifying active GLA-domain coagulation proteins Grant 9,212,365 - Perret , et al. December 15, 2	2015-12-15
Use Of Adcc-optimized Antibodies For Treating Weak Patients App 20150307624 - Bourel; Dominique ; et al.	2015-10-29
Monoclonal Antibodies With Enhanced Adcc Function App 20150266972 - BELIARD; Roland ; et al.	2015-09-24
Use of ADCC-optimized antibodies for treating weak patients Grant 9,109,020 - Bourel , et al. August 18, 2	2015-08-18
Monoclonal Antibodies With Enhanced Adcc Function App 20150152189 - Beliard; Roland ; et al.	2015-06-04
Monoclonal Antibodies With Enhanced Adcc Function App 20140162356 - Beliard; Roland ; et al.	2014-06-12
Recombinant Or Transgenic Factor Vii Composition, Each Factor Vii Molecule Having Two N-glycosylation Sites With Defined Glycan Units App 20140093491 - Chtourou; Abdessatar Sami ; et al.	2014-04-03
Monoclonal antibodies with enhanced ADCC function Grant 8,685,725 - Beliard , et al. April 1, 2	2014-04-01
Use Of Adcc-optimized Antibodies For Treating Weak Patients App 20140017243 - Bourel; Dominique ; et al.	2014-01-16
Use of ADCC-optimized antibodies for treating weak patients Grant 8,501,171 - Bourel , et al. August 6, 2	2013-08-06
Recombinant Or Transgenic Factor Vii Compound Having A Majority Of Glycan, Biantennary, Bisialylated And Non-fucosylated Forms App 20130189244 - Chtourou; Abdessatar Sami ; et al.	2013-07-25
Method For Purifying Gla-domain Coagulation Proteins App 20130143302 - Perret; Gerald ; et al.	2013-06-06
Monoclonal antibodies with enhanced ADCC function Grant 8,409,572 - Beliard , et al. April 2, 2	2013-04-02
Anti-D monoclonal antibodies Grant 8,357,370 - Beliard , et al. January 22, 2	2013-01-22
Method For Purifying Active Gla-domain Coagulation Proteins App 20120271039 - Perret; Gerard ; et al.	2012-10-25
Monoclonal Antibodies With Enhanced Adcc Function App 20120259095 - Beliard; Roland ; et al.	2012-10-11
Anti-d Monoclonal Antibodies App 20120258096 - Beliard; Roland ; et al.	2012-10-11
Method for treating infectious disease using monoclonal antibodies Grant 8,178,093 - Beliard , et al. May 15, 2	2012-05-15
Method for treating cancer using monoclonal antibodies Grant 8,153,124 - Beliard , et al. April 10, 2	2012-04-10
Method for treating idiopathic thrombocytopenic purpura using monoclonal antibodies Grant 8,124,078 - Beliard , et al. February 28, 2	2012-02-28
Monoclonal Antibodies With Enhanced Adcc Function App 20110223658 - Beliard; Roland ; et al.	2011-09-15
Modified Human Factor Vii/viia And Pharmaceutical Composition Containing The Same App 20110162094 - Nony; Emmanuel ; et al.	2011-06-30
Monoclonal antibodies with enhanced ADCC function Grant 7,931,895 - Beliard , et al. April 26, 2	2011-04-26
Method For Treating Cancer Using Monoclonal Antibodies App 20110059072 - Beliard; Roland ; et al.	2011-03-10
Method For Treating Infectious Disease Using Monoclonal Antibodies App 20110059073 - BELIARD; ROLAND ; et al.	2011-03-10
Method For Treating Idiopathic Thrombocytopenic Purpura Using Monoclonal Antibodies App 20110052571 - Beliard; Roland ; et al.	2011-03-03
Cytokine production-inducing antibody App 20100323368 - de Romeuf; Christophe ; et al.	2010-12-23
Use of ADCC-Optimized antibodies for treating weak patients App 20100303826 - Bourel; Dominique ; et al.	2010-12-02
Preparation of human, humanized or chimaeric antibodies or polypeptides having different binding profiles to Fcgamma receptors Grant 7,790,399 - Bourel , et al. September 7, 2	2010-09-07
Use of ADCC-optimized antibodies for treating low-responder patients Grant 7,713,524 - Bourel , et al. May 11, 2	2010-05-11
Recombinant Or Transgenic Factor Vii Composition, Each Factor Vii Molecule Having Two N-glycosylation Sites With Defined Glycan Units App 20090311239 - Chtourou; Abdessatar Sami ; et al.	2009-12-17
Method of measuring activation of effector cells Grant 7,595,165 - Romeuf , et al. September 29, 2	2009-09-29
Recombinant Or Transgenic Factor Vii Compound Having A Majority Of Glycan, Biantennary, Bisialylated And Non-fucosylated Forms App 20090239788 - Chtourou; Abdessatar Sami ; et al.	2009-09-24
Method for preparing monoclonal antibodies capable of activating effector cells expressing FC.gamma.RIII Grant 7,579,170 - Beliard , et al. August 25, 2	2009-08-25
Anti-rhesus D monoclonal antibodies Grant 7,541,029 - Beliard , et al. June 2, 2	2009-06-02
Novel lgG3 Antibodies for Stimulating Phagocytosis App 20070218052 - Romeuf; Christophe De ; et al.	2007-09-20
Therapeutic products with enhance ability to immunomodulate cell functions App 20070135621 - Bourel; Dominique ; et al.	2007-06-14
Correlation between the fucose content/galactose content ratio of anti-rhesus-d and anti-hla-dr antibodies and the adcc activity App 20070015239 - Bihoreau; Nicolas ; et al.	2007-01-18
Anti-Rhesus D monoclonal antibodies App 20070009522 - Beliard; Roland ; et al.	2007-01-11
Use of adcc-optimized antibodies for treating weak patients App 20060182741 - Bourel; Dominique ; et al.	2006-08-17

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.